Evidence map›Paper›PMID 30552009›Full record

ArticleBioorganic & medicinal chemistry2019

Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors.

Cyril Barinka, Zora Novakova, Niyada Hin, Daniel Bím, Dana V Ferraris, Bridget Duvall, Gabriel Kabarriti, Reiji Tsukamoto, Milos Budesinsky, Lucia Motlova and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 29 citations in OpenAlex.

  1. Combination ofJournal of chemical information and modeling · 2023
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies.International journal of molecular sciences · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Cyril BarinkaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic. Electronic address: cyril.barinka@ibt.cas.cz.
Zora NovakovaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.
Niyada HinJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
Daniel BímInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic.
Dana V FerrarisMcDaniel College, 2 College Hill, Westminster MD 21157, United States.
Bridget DuvallJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
Gabriel KabarritiJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
Reiji TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
Milos BudesinskyInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic.
Lucia MotlovaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.
Camilo RojasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD 21205, United States.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States.
Tibor András RokobInstitute of Organic Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, 1117 Budapest, Magyar Tudósok körútja 2, Hungary.
Lubomír RulíšekInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic. Electronic address: lubomir.rulisek@uochb.cas.cz.
Takashi TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States. Electronic address: ttskuamoto@jhmi.edu.
Johns Hopkins University · USCzech Academy of Sciences, Institute of Biotechnology · CZCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZInstitute of Organic Chemistry · HUMcDaniel College · US

Funding

Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Leah Helane Rubin · 2006 to 2026
$33.2M
Surrogate Marker CoreP01MH105280 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C · 2015 to 2019
$6.5M
Targeting glutamate carboxypeptidase in perinatal brain injuryR01NS093416 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Sujatha Kannan, Kannan Rangaramanujam · 2016 to 2026
$4.8M
Translational Research in Neuro-AIDS and Mental HealthR25MH080661 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MCARTHUR, JUSTIN CHARLES. · 2007 to 2019
$2.9M
Exosomes:From biogenesis and secretion to the early pathogenesis of Alzheimer's diseaseR01AG057420 · NIA · JOHNS HOPKINS UNIVERSITY · PI HAUGHEY, NORMAN J · 2017 to 2021
$2.0M
Dysregualtion of gliotransmission in models of neuroHIVR01MH110246 · NIMH · JOHNS HOPKINS UNIVERSITY · PI HAUGHEY, NORMAN J · 2016 to 2020
$2.0M
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathyR01CA161056 · NCI · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH · 2012 to 2016
$1.8M
NCI NIH HHS R01 CA161056NIA NIH HHS R01 AG057420NIMH NIH HHS P01 MH105280NIMH NIH HHS P30 MH075673NIMH NIH HHS R01 MH110246NIMH NIH HHS R25 MH080661NINDS NIH HHS R01 NS093416
6 · The paper itself

Abstract

A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII's preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.

Indexed as

AnimalsCarbamatesCatalytic DomainCell LineDrosophilaEnzyme AssaysGlutamate Carboxypeptidase IIHumansHydrogen BondingModels, MolecularProtease InhibitorsProtein BindingQuantum TheoryStereoisomerismUreaCarbamatesGlutamate Carboxypeptidase IIProtease InhibitorsUreaZJ43Crystal structureGlutamate carboxypeptidase IIMetallopeptidaseProstate-specific membrane antigen

Identifiers

PMID30552009
PMCPMC6374116
OpenAlexW2900485803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.